Toxicity of (neo)adjuvant chemotherapy for BRCA1- and BRCA2-associated breast cancer

about

Cytotoxic and targeted therapy for hereditary cancers

P2860

Q26739366-5E1A82AC-B9D1-474B-9521-9BBA6EA0E789

P2860

Toxicity of (neo)adjuvant chemotherapy for BRCA1- and BRCA2-associated breast cancer

Item

http://www.wikidata.org/entity/Q36814437

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Toxicity of (neo)adjuvant chemotherapy for BRCA1- and BRCA2-associated breast cancer

@ast

Toxicity of (neo)adjuvant chemotherapy for BRCA1- and BRCA2-associated breast cancer

@en

type

Item

label

Toxicity of (neo)adjuvant chemotherapy for BRCA1- and BRCA2-associated breast cancer

@ast

Toxicity of (neo)adjuvant chemotherapy for BRCA1- and BRCA2-associated breast cancer

@en

prefLabel

Toxicity of (neo)adjuvant chemotherapy for BRCA1- and BRCA2-associated breast cancer

@ast

Toxicity of (neo)adjuvant chemotherapy for BRCA1- and BRCA2-associated breast cancer

@en

P1476

Toxicity of (neo)adjuvant chemotherapy for BRCA1- and BRCA2-associated breast cancer

@en

P2093

Agnes Jager

http://www.w3.org/2001/XMLSchema#string

Bernadette A M Heemskerk-Gerritsen

http://www.w3.org/2001/XMLSchema#string

Cynthia Epskamp

http://www.w3.org/2001/XMLSchema#string

Jan C Drooger

http://www.w3.org/2001/XMLSchema#string

Nyrée Smallenbroek

http://www.w3.org/2001/XMLSchema#string

P2860

Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies

Meta-analysis of BRCA1 and BRCA2 penetrance

Cancer susceptibility and the functions of BRCA1 and BRCA2

Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial.

Sensitivity to first-line chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers.

Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.

Impact of chemotherapy dose intensity on cancer patient outcomes.

Evaluating the impact of Relative Total Dose Intensity (RTDI) on patients' short and long-term outcome in taxane- and anthracycline-based chemotherapy of metastatic breast cancer- a pooled analysis.

Homologous repair of DNA damage and tumorigenesis: the BRCA connection.

The role of BRCA1 in the cellular response to chemotherapy.

P2888

s10549-016-3777-0

P304

557-566

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10549-016-3777-0

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

156

http://www.w3.org/2001/XMLSchema#string

P50

Caroline Seynaeve

P577

2016-04-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27060914

http://www.w3.org/2001/XMLSchema#string

P932

4837227

http://www.w3.org/2001/XMLSchema#string

Toxicity of (neo)adjuvant chemotherapy for BRCA1- and BRCA2-associated breast cancer

about

P2860

P2860

Toxicity of (neo)adjuvant chemotherapy for BRCA1- and BRCA2-associated breast cancer

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932